Compositive compounds | \(\phi ^{DC}\) | \(\phi ^{BC}\) | \(\phi ^{CC}\) |
---|---|---|---|
Glycidyl oleate | 0.5342 | 0.0485 | 0.5581 |
Glyceryl-2 palmitate | 0.5109 | 0.0517 | 0.5892 |
Oleoyl chloride | 0.4589 | 0.0528 | 0.4706 |
9-Octadecenoic acid (Z)-, methyl ester | 0.4316 | 0.0525 | 0.4752 |
Methyl stearate | 0.4446 | 0.0489 | 0.4468 |
Hexadecanoic acid, methyl ester | 0.4472 | 0.0532 | 0.4656 |
Hexadecanoic acid, 2,3-bis(acetyloxy)propyl ester | 0.4912 | 0.1413 | 0.4842 |
Glyceryl diacetate-2-Oleate | 0.4509 | 0.0517 | 0.4892 |
Known RA targets | |||
Nitric oxide synthase | 0.4982 | 0.0565 | 0.5681 |
Interleukin-1\(\beta\) | 0.4106 | 0.0493 | 0.4855 |
Delta-type opioid receptor | 0.5417 | 0.1199 | 0.4944 |
Tumor necrosis factor | 0.4626 | 0.1696 | 0.4896 |
Prostaglandin G/H synthase 2 | 0.4933 | 0.3967 | 0.5411 |
Prostaglandin G/H synthase 1 | 0.4551 | 0.5040 | 0.4794 |
Growth-regulated alpha protein | 0.4126 | 0.0888 | 0.5249 |
C–C chemokine receptor type 5 | 0.4026 | 0.0589 | 0.4609 |
Interleukin-6 | 0.4244 | 0.0671 | 0.5158 |
Cannabinoid receptor 2 | 0.4700 | 0.0401 | 0.4352 |
Putative targets | |||
TNF | 0.2705 | 0.0921 | 0.0588 |
CXCL10 | 0.1728 | 0.0116 | 0.5640 |
IL10 | 0.1728 | 0.0125 | 0.5433 |
IL6 | 0.3004 | 0.0930 | 0.5402 |
CXCL1 | 0.1044 | 0.0151 | 0.5432 |
CXCL8 | 0.1273 | 0.0160 | 0.5439 |
FOXP3 | 0.4106 | 0.0149 | 0.3748 |
CCR2 | 0.3004 | 0.0161 | 0.4762 |
CCR5 | 0.3004 | 0.0279 | 0.4922 |
IL10 | 0.1273 | 0.0145 | 0.5302 |
CCL2 | 0.2495 | 0.0190 | 0.4548 |
IL1B | 0.1405 | 0.0253 | 0.5838 |
IL17 | 0.2495 | 0.0195 | 0.5374 |
IL13 | 0.2212 | 0.0252 | 0.5347 |
CSF2 | 0.2905 | 0.0996 | 0.5101 |